Primary Immune Deficiency (PID) - Pipeline Review, H1 2017

Publisher Name :
Date: 08-Mar-2017
No. of pages: 79
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2017, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.

Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 7, 1, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 3 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).

  • The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Primary Immune Deficiency (PID) - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Immune Deficiency (PID) - Overview
Primary Immune Deficiency (PID) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Primary Immune Deficiency (PID) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
ADMA Biologics Inc
Biotest AG
Genethon SA
GigaGen Inc
GlaxoSmithKline Plc
Green Cross Corp
Novartis AG
Octapharma AG
ProMetic Life Sciences Inc
Sangamo Therapeutics Inc
Shire Plc
Taiga Biotechnologies Inc
UCB SA
X4 Pharmaceuticals Inc
Primary Immune Deficiency (PID) - Drug Profiles
Antibody for Primary Immune Deficiency Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for RAG-Deficient Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency Related SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2696273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) next generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RI-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seletalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for ADA Deficiency Related SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Hematological Disorders and Primary Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Leukocyte Adhesion Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Severe Combined Immunodeficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Artemis for SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBX-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-4P001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Immune Deficiency (PID) - Dormant Projects
Primary Immune Deficiency (PID) - Product Development Milestones
Featured News & Press Releases
Nov 29, 2016: Option Care Has Been Selected as a National Provider of CUVITRU
Nov 23, 2016: Green Cross Receives Complete Response Letter from US FDA for IVIG-SN
Nov 16, 2016: Shire Launches CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency
Nov 12, 2016: Tolerability Data for Shires Cuvitru Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting
Sep 23, 2016: Shire To Showcase Data On Cuvitru During European Society For Immunodeficiencies Biennial Meeting
Sep 14, 2016: Shire Announces U.S. FDA Approval of CUVITRU Treatment for Primary Immunodeficiency
Aug 09, 2016: ProMetic Completes Adult Patients Enrolment in Pivotal IVIG Phase 3 Clinical Trial
Jun 10, 2016: Shire announces completion of decentralized procedure in Europe for Immunoglobulin Treatment Cuvitru
Mar 07, 2016: Green Cross Biotherapeutics Receives Health Canada Approval for Phase III Clinical Trials of IVIG 10%
Mar 03, 2016: Baxalta to Showcase Innovation Leadership in Primary Immune Deficiencies During 2016 American Academy of Allergy, Asthma & Immunology Annual Meeting
Jan 25, 2016: US FDA Accepts Green Cross' Biologics License Application for IVIG-SN
Dec 02, 2015: Baxalta Receives CHMP Positive Opinion on GAMMAGARD
Nov 24, 2015: Green Cross Submits Biologics License Application to US FDA for IVIG-SN
Oct 26, 2015: Prometic's IVIG IND Cleared By FDA
May 21, 2015: Baxter BioScience Files for European Approval of Investigational 20% Subcutaneous Immune Globulin Treatment for Primary Immunodeficiency
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Primary Immune Deficiency (PID), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, H1 2017
Primary Immune Deficiency (PID) - Pipeline by Biotest AG, H1 2017
Primary Immune Deficiency (PID) - Pipeline by Genethon SA, H1 2017
Primary Immune Deficiency (PID) - Pipeline by GigaGen Inc, H1 2017
Primary Immune Deficiency (PID) - Pipeline by GlaxoSmithKline Plc, H1 2017
Primary Immune Deficiency (PID) - Pipeline by Green Cross Corp, H1 2017
Primary Immune Deficiency (PID) - Pipeline by Novartis AG, H1 2017
Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H1 2017
Primary Immune Deficiency (PID) - Pipeline by ProMetic Life Sciences Inc, H1 2017
Primary Immune Deficiency (PID) - Pipeline by Sangamo Therapeutics Inc, H1 2017
Primary Immune Deficiency (PID) - Pipeline by Shire Plc, H1 2017
Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, H1 2017
Primary Immune Deficiency (PID) - Pipeline by UCB SA, H1 2017
Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, H1 2017
Primary Immune Deficiency (PID) - Dormant Projects, H1 2017

List of Figures

Number of Products under Development for Primary Immune Deficiency (PID), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Global Varicose Vein Treatment Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 24-Mar-2017        Price: US 3480 Onwards        Pages: 118
    There are several treatment options for Varicose Veins, wearing support stockings, Varicose Vein Treatment Devices; endogenous laser treatment, radiofrequency occlusion, surgery, and lasers and intense pulsed light. Mentioning medical devices for treating Varicose Veins, there is mainly Laser devices, Trivex and RFITT system. Scope of the Report: This report focuses on the Varicose Vein Treatment in Global market, especially in North America, Europe and Asia-Pacific......
  • Liver Cirrhosis - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 96
    Liver Cirrhosis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver ......
  • Becker Muscular Dystrophy - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 40
    Becker Muscular Dystrophy - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy - Pipeline Review, H1 2017, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape. Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms in......
  • Duchenne Muscular Dystrophy - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 275
    Duchenne Muscular Dystrophy - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2017, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape. Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder. The gene for DMD is present on the X chromosome. It co......
  • Fabry Disease - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 67
    Fabry Disease - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called globotriaosylceramide) in blood vessel walls throughout the body. Symptom......
  • Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 82
    Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape. Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms......
  • Bone Marrow Transplant Rejection - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 455
    Bone Marrow Transplant Rejection - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells at......
  • Dyslipidemia - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 280
    Dyslipidemia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipop......
  • Therapy Companies in China
    Published: 18-Mar-2017        Price: US 1800 Onwards        Pages: 88
    This study focuses on China's Therapy industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods an......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs